• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Personalis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/19/25 4:10:07 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email
    8-K
    false000152775300015277532025-05-162025-05-16

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 16, 2025

     

    Personalis, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38943

    27-5411038

    (State or Other Jurisdiction

    of Incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

     

     

     

    6600 Dumbarton Circle

    Fremont, California

     

    94555

    (Address of Principal Executive Offices)

    (Zip Code)

    (650) 752-1300

    Registrant’s Telephone Number, Including Area Code

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    PSNL

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On May 16, 2025, Personalis, Inc. (the “Company”) virtually held its 2025 annual meeting of stockholders (the “Annual Meeting”). Present at the Annual Meeting virtually or by proxy were the holders of 76,834,155 shares of common stock of the Company, representing 87.0% of the 88,308,207 shares of common stock outstanding as of the close of business on March 20, 2025, the record date for the Annual Meeting, and constituting a quorum for the transaction of business.

    At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 3, 2025. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for or against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter.

    Proposal 1. Stockholders elected each of the two nominees for Class III director to serve until the Company’s 2028 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified or, if sooner, until the director's death, resignation or removal. The voting results were as follows:

     

    Director Name

     

    Votes For

     

    Votes Withheld

     

    Broker Non-Votes

    A. Blaine Bowman

     

    58,176,978

     

    710,080

     

    17,947,097

    Karin Eastham

     

    53,717,529

     

    5,169,529

     

    17,947,097

    Proposal 2. Stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The voting results were as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

    76,612,188

     

    110,157

     

    111,810

    Proposal 3. Stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    56,604,799

     

    2,244,133

     

    38,126

     

    17,947,097

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: May 19, 2025

    Personalis, Inc.

     

     

    By:

    /s/ Aaron Tachibana

     

    Aaron Tachibana

     

    Chief Financial Officer and Chief Operating Officer

     

     


    Get the next $PSNL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    1/7/2022$27.00 → $23.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection. "These studies continue to expand the clinical data for NeXT Personal into new areas, including neoadjuvant treatment in breast cancer and cervical cancer," said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. "We continue to be driven by our mission to provide physicians and thei

      5/22/25 6:00:00 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025, at The Depot Renaissance Hotel in Minneapolis, MN. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed

      5/14/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Reports First Quarter 2025 Financial Results

      Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study

      5/6/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      3/5/24 5:15:53 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    SEC Filings

    See more
    • Personalis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Personalis, Inc. (0001527753) (Filer)

      5/19/25 4:10:07 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.

      SCHEDULE 13G/A - Personalis, Inc. (0001527753) (Subject)

      5/14/25 10:39:48 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Personalis Inc.

      10-Q - Personalis, Inc. (0001527753) (Filer)

      5/6/25 4:24:12 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO AND COO Tachibana Aaron sold $6,390 worth of shares (1,291 units at $4.95), decreasing direct ownership by 0.78% to 165,099 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:53:11 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • SVP and Chief Legal Officer Moore Stephen Michael sold $8,291 worth of shares (1,675 units at $4.95), decreasing direct ownership by 3% to 64,200 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:51:51 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • CHIEF MEDICAL OFFICER AND EVP Chen Richard sold $4,504 worth of shares (910 units at $4.95), decreasing direct ownership by 0.72% to 124,957 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:50:02 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Personalis Inc.

      SC 13G/A - Personalis, Inc. (0001527753) (Subject)

      8/19/24 6:03:38 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Personalis Inc.

      SC 13G - Personalis, Inc. (0001527753) (Subject)

      7/26/24 12:56:21 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Personalis Inc.

      SC 13D/A - Personalis, Inc. (0001527753) (Subject)

      6/28/24 4:01:17 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Financials

    Live finance-specific insights

    See more
    • Personalis Reports First Quarter 2025 Financial Results

      Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study

      5/6/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis to Announce First Quarter 2025 Financial Results

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusio

      4/22/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

      Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. Recent Business Highlights Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024; delivered 3,285 total molecular tests for the full year of 2024 compared with 177 in 2023 Submitted for Medicare coverage in early

      2/27/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Personalis with a new price target

      Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

      5/15/25 8:13:23 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Canaccord Genuity initiated coverage on Personalis with a new price target

      Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

      3/17/25 8:20:27 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis upgraded by Needham with a new price target

      Needham upgraded Personalis from Hold to Buy and set a new price target of $8.00

      2/6/23 9:09:41 AM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    See more
    • Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

      Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

      10/18/23 7:15:00 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Dr. Kenneth J. Widder Joins Personalis Board of Directors

      Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

      6/13/23 7:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Announces CEO Retirement and Transition

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th

      12/14/22 4:02:00 PM ET
      $PSNL
      Medical Specialities
      Health Care